Quick Hits: FDA Approves Biologic for Cancers With Genetic Defects, Prescription Drug Prices Soar & More

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

The FDA gave accelerated approval to the biologic Keytruda (pembrolizumab) for patients whose solid cancer tumors have a specific genetic feature. This is the first time the agency has approved a drug based on a such a feature, also known as a biomarker. In the past, the FDA has approved cancer treatments based on where in the body the cancer started (e.g., lung or breast cancers). Patients taking Keytruda should take precautions as the medication can cause serious conditions known as immune-mediated side effects, including inflammation of healthy organs such as the lungs, colon, liver, endocrine glands and kidneys. Additionally, it may cause harm to a developing fetus or newborn baby. Posted May 23, 2017. Via FDA.

Prescription drug prices increased by an average 8.8% in 2016. This represents the fourth consecutive year of inflation above 8%, according to data from the Truveris National Drug Index. Over the last 3 years, the average annual price increase was nearly 10%. Furthermore, drug prices inflated 318% more than the price of all goods in the US. Posted May 10, 2017. Via PR Newswire.

The FDA’s Office of Prescription Drug Promotion sent a warning letter to Orexigen Therapeutics for a television advertisement that conveyed a misleading impression about the safety of its weight loss drug Contrave. The TV ad fails to disclose any information about neuropsychiatric reactions discussed in the Boxed Warning section of the labeling for Contrave (naltrexone/bupropion). The TV ad misleadingly suggests that Contrave is safer than has been demonstrated by omitting serious risks associated with the medication, according to the FDA. Orexigen has until June 2 to respond to the letter. Posted May 18, 2017. Via FDA.


Alanna McCatty

Alanna McCatty

Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement